[London, UK] – October 9, 2025 – Asymchem Laboratories., a global leader in CDMO services, successfully hosted its European Symposium at The Shard, one of London’s most iconic landmarks.
Under the theme “Sustainable Synthesis Reimagined: The New Horizon through High Throughput Experimentation, Flow Chemistry & Biocatalysis,” the event convened leading experts from academia and the pharmaceutical industry to share insights on the latest advancements shaping the future of sustainable synthesis. The symposium served as an engaging platform for dialogue on pioneering technologies, process innovation, and best practices advancing greener, more efficient drug development.
The symposium featured four distinguished speakers from both academia and industry who delivered thought-provoking presentations on integrating advanced technologies to enhance sustainability and efficiency in pharmaceutical R&D and manufacturing. A thought-provoking panel discussion further examined how sustainability is evolving beyond cost efficiency to become a true source of competitive advantage—fueling lively dialogue and collaboration among participants.
Steve Fussell, Senior Manager of High Throughput Experimentation at Asymchem UK Sandwich Site
Prof. Thomas Chamberlain, Professor of Digital and Materials Chemistry at the University of Leeds
In his opening remarks, Dr. Guoxi Zheng, Senior Vice President of Asymchem, responsible for Site Operations at the Sandwich facility, noted:
“Building on our strong foundation in small molecules, we are actively expanding into new modalities. Our first European core facility in Sandwich, UK, marks a major milestone, showcasing our commitment to sustainable pharmaceutical process development through advanced sustainable chemistry and automation.”
In his closing address, Dr. Cheng Yi Chen, Chief Technology Officer of Asymchem, emphasized the event’s role in fostering future collaboration:
“This symposium has been an outstanding success. We look forward to reconvening next year to continue building partnerships and driving scientific innovation together.”
Dr. Cheng Yi Chen, CTO at Asymchem
The event received highly positive feedback from attendees, with speakers commending the excellent venue and well-balanced agenda that combined deep technical insights from Asymchem and external experts.
Following the technical sessions, guests continued their discussions over a drinks and canapé reception, which offered a warm and relaxed atmosphere for networking and exploring new opportunities for collaboration.
The symposium reaffirmed Asymchem’s dedication to advancing pharmaceutical innovation and sustainability in close collaboration with global partners.
About Asymchem:
Asymchem (Stock Code: 002821.SZ / 6821.HK) is a leading global CDMO established in 1995 in North Carolina, U.S., dedicated to delivering integrated, end-to-end solutions across the pharmaceutical value chain. Operating from a global network of R&D and manufacturing facilities in China, the U.S and UK, Asymchem employs more than 9,000 professionals worldwide, with 45% of those dedicated to R&D.
Leveraging a robust technical foundation and global infrastructure, Asymchem provides fundamental development and commercial manufacturing services in response to the growing complexity of modern drug development. With decades of innovation and execution, Asymchem has evolved from a small molecule CDMO into a diversified partner supporting a wide range of modalities, including TIDES, biologics, drug products, clinical research, synthetic biology, and technology transfer.
Trusted by more than 1,000 clients worldwide, including top 20 pharmaceutical companies and leading biotechs, backed by a proven track record of USFDA and other agency inspections, Asymchem supports over 700 clinical-stage projects and more than 40 commercial production projects for clients around the globe. These projects are underpinned by our strong commitment to cGMP compliance and environmental health and safety (EHS).
Asymchem helps accelerate drug development, reduce time to market, and deliver client-centric, cost-effective solutions tailored to the complex challenges of modern pharmaceutical innovation.
For more information, please visit: http://www.asymchem.com
Follow us on LinkedIn: http://www.linkedin.com/company/asymchem
Contacts:
Monica Wilson, Esq.
Asymchem, Inc.
inquiry@asymchem.com
